抗心衰药物的研究进展

Research progress of anti-heart failure drug

慢性心衰是各种心脏疾病的终末阶段,主要特征为呼吸困难、水肿、乏力等。近年来,慢性心衰患者发病率与病死率逐年上升,对患者的生理、心理状态和生活质量造成了严重的影响。随着抗心衰药物研究的不断发展,不少新药被广泛的运用到了心衰患者的治疗当中,其中血管紧张素受体脑啡肽酶抑制剂不仅能够改善患者的射血分数,降低死亡风险,还可缩短患者的住院时间,促进患者早日康复,已成为了目前国内外治疗心衰指南推荐的药物。对于心衰患者而言,血管紧张素受体脑啡肽酶抑制剂不仅安全性高,而且能帮助患者维持血流动力学稳定。此外,钠-葡萄糖协同转运蛋白2抑制剂也具有同样的治疗效果,能够增强患者葡萄糖与钠经尿液排泄,降低患者的死亡风险,缩短住院治疗时间,同时其他的抗心衰药物的研究也取得了良好的成效。基于此,本文对抗心衰药物的研究进展进行了综述,希望为临床心衰患者的治疗提供帮助。

Chronic heart failure is the final stage of various heart disease,which is mainly characterized by dyspnea,edema,fatigue,etc.In recent years,the morbidity and mortality of patients with chronic heart failure have increased year by year,which has a serious impact on patients’ physiological,psychological and quality of life.With the continuous development of anti-heart failure drug research,many new drugs have been widely used in the treatment of patients with heart failure.Among them,angiotensin receptor enkephalinase inhibitors can not only improve the ejection fraction and reduce the risk of death of patients,but also shorten the hospitalization time and promote the early recovery of patients,which have become the drugs recommended by the treatment guidelines for heart failure at home and abroad.For patients with heart failure,angiotensin receptor enkephalinase inhibitors not only have high safety,but also can help patients maintain hemodynamic stability.In addition,sodium-glucose cotransporter 2 inhibitors have the same therapeutic effect,which can enhance the excretion of glucose and sodium in urine,reduce the risk of death and shorten the hospitalization time.Meanwhile,other anti-heart failure drugs have also achieved good results.Based on this,this paper reviews the research progress of anti-heart failure drugs,hoping to provide help for the clinical treatment of patients with heart failure.